BeOne Medicines (ONC) Stock Price, News & Analysis

Company Overview

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Key Stats

• Today's Range: $357.79 to $364.61
• 50-Day Range: $279.89 to $376.86
• 52-Week Range: $253.95 to $385.22
• Volume: 123,616 shs
• Average Volume: 394,782 shs
• Market Capitalization: $39.82 billion
• P/E Ratio: 63.69
• Dividend Yield: N/A
• Price Target: $402.14
• Consensus Rating: Buy

BeOne Medicines Stock Analysis - MarketRank™

BeOne Medicines scored higher than 75% of companies evaluated by MarketBeat, and ranked 155th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Buy

Consensus Rating

BeOne Medicines has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 strong buy ratings, 12 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

BeOne Medicines has a consensus price target of $402.14, representing about 10.9% upside from its current price of $362.68.

Amount of Analyst Coverage

BeOne Medicines has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 54.71%

Earnings Growth

Earnings for BeOne Medicines are expected to grow by 54.71% in the coming year, from $8.81 to $13.63 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BeOne Medicines is 63.85, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.20.

Price to Earnings Ratio vs. Sector

The P/E ratio of BeOne Medicines is 63.85, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.59.

Price to Book Value per Share Ratio

BeOne Medicines has a P/B Ratio of 7.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.24% of the float of BeOne Medicines has been sold short.

Short Interest Ratio / Days to Cover

BeOne Medicines has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BeOne Medicines has recently increased by 44.91%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BeOne Medicines does not currently pay a dividend.

Dividend Growth

BeOne Medicines does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.53

News Sentiment

BeOne Medicines has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for BeOne Medicines this week, compared to 6 articles on an average week.

Search Interest

8 people have searched for ONC on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.

MarketBeat Follows

6 people have added BeOne Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BeOne Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $192,918,836.00 in company stock.

Percentage Held by Insiders

6.19% of the stock of BeOne Medicines is held by insiders.

Percentage Held by Institutions

48.55% of the stock of BeOne Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/03/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ONC
• Previous Symbol: NASDAQ:ONC
• CIK: 1651308
• Web: beigene.com
• Phone: 13459494123
• Fax: N/A
• Employees: 12,000
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BeOne Medicines: $402.14
• High Price Target: $454.00
• Low Price Target: $290.00
• Potential Upside/Downside: +10.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $5.68
• Trailing P/E Ratio: 63.69
• Forward P/E Ratio: 41.17
• P/E Growth: N/A
• Net Income: $286.93 million
• Net Margins: 10.70%
• Pretax Margin: 14.16%
• Return on Equity: 14.23%
• Return on Assets: 7.82%

Debt

• Debt-to-Equity Ratio: 0.17
• Current Ratio: 3.40
• Quick Ratio: 3.06

Sales & Book Value

• Annual Sales: $5.34 billion
• Price / Sales: 7.45
• Cash Flow: $3.92 per share
• Price / Cash Flow: 92.56
• Book Value: $47.13 per share
• Price / Book: 7.70

Miscellaneous

• Outstanding Shares: 109,790,000
• Free Float: 102,991,000
• Market Cap: $39.82 billion
• Optionable: N/A
• Beta: 0.51